A detailed history of Black Rock Inc. transactions in Armata Pharmaceuticals, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 22,921 shares of ARMP stock, worth $44,695. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,921
Previous 23,868 3.97%
Holding current value
$44,695
Previous $99,000 36.36%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$2.4 - $3.9 $2,272 - $3,693
-947 Reduced 3.97%
22,921 $63,000
Q1 2024

May 10, 2024

BUY
$2.81 - $4.18 $3,113 - $4,631
1,108 Added 4.87%
23,868 $99,000
Q4 2023

Feb 13, 2024

SELL
$1.95 - $3.24 $518 - $861
-266 Reduced 1.16%
22,760 $73,000
Q3 2023

Nov 13, 2023

SELL
$1.1 - $4.35 $1,529 - $6,046
-1,390 Reduced 5.69%
23,026 $69,000
Q2 2023

Aug 11, 2023

SELL
$1.14 - $1.7 $1,085 - $1,618
-952 Reduced 3.75%
24,416 $27,000
Q1 2023

May 12, 2023

BUY
$1.1 - $3.58 $897 - $2,921
816 Added 3.32%
25,368 $42,000
Q4 2022

Feb 13, 2023

BUY
$0.94 - $4.16 $511 - $2,263
544 Added 2.27%
24,552 $30,000
Q3 2022

Nov 14, 2022

BUY
$3.12 - $4.92 $7,394 - $11,660
2,370 Added 10.95%
24,008 $101,000
Q2 2022

Aug 12, 2022

SELL
$2.97 - $5.4 $8,984 - $16,335
-3,025 Reduced 12.27%
21,638 $84,000
Q1 2022

May 12, 2022

SELL
$3.9 - $6.32 $4,668 - $7,565
-1,197 Reduced 4.63%
24,663 $121,000
Q4 2021

Feb 10, 2022

BUY
$2.96 - $5.86 $15,655 - $30,993
5,289 Added 25.71%
25,860 $142,000
Q3 2021

Nov 09, 2021

BUY
$3.55 - $4.14 $65,923 - $76,879
18,570 Added 928.04%
20,571 $74,000
Q2 2021

Aug 11, 2021

BUY
$3.89 - $4.87 $7,783 - $9,744
2,001 New
2,001 $8,000

Others Institutions Holding ARMP

About Armata Pharmaceuticals, Inc.


  • Ticker ARMP
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,144,700
  • Market Cap $70.5M
  • Description
  • Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus ...
More about ARMP
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.